SecBot SecBot
PRESS-RELEASE ·Filed Apr 1, 2026

INKT

MiNK Therapeutics
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should monitor the ATS conference presentation on May 20 for initial data on agenT-797's immune restoration potential in severe infections, which could influence near-term sentiment. Until then, no material change in valuation is supported.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.57
T+0 close · Apr 1, 2026 · via day close
Latest settled
+12.68%
T+60 · $11.91
Vs SPY
−0.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $10.57entry
  2. T+1 · 8mo ago +1.14%α +1.06% · $10.69
  3. T+5 · 7mo ago +8.51%α +4.75% · $11.47
  4. T+20 · 7mo ago +11.73%α +2.01% · $11.81
  5. T+60 · 5mo ago +12.68%α −0.70% · $11.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, in combination with N-803 for severe Coccidioides infection, has been accepted for presentation at the ATS International Conference in May 2026. No data will be disclosed ahead of the conference, and full results will be shared during the poster session. This represents early-stage clinical visibility but no new efficacy or safety results.

Key Facts

  • Abstract on agenT-797 combination therapy accepted for poster presentation at ATS 2026 conference.
  • Presentation will occur on May 20, 2026, in Orlando, Florida; no data released in advance.
  • agenT-797 is in clinical development for GvHD, solid tumors, and severe pulmonary inflammation.
  • No financial or clinical results disclosed; next update expected at the conference.

Financial Impact

No immediate financial impact; potential for sentiment shift post-data disclosure

pipeline valueR&D progress

Risk Factors

  • No data available yet, clinical benefit remains unproven
  • High risk typical of early-stage biotech development; future results may not meet expectations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3266508

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026